Clinuvel Pharmaceuticals Limited Sponsored ADR (CUVL) Stock Price & Analysis
CUVL Stock Chart & Stats
- Day’s Range
- $4.95 - $6.11
- 52-Week Range
- $4.88 - $8.78
- Previous Close
- $5.15
- Volume
- 1,256
- Average Volume (3M)
- 7,542
- Market Cap
- $256.33M
- Enterprise Value
- $188.54M
- Total Cash (Recent Filing)
- N/A
- Total Debt (Recent Filing)
- N/A
- Price to Earnings (P/E)
- 11.0
- Beta
- 0.75
- Next Earnings
- Feb 23, 2027 (Est.)
- EPS Estimate
- 0.18
- Last Dividend Ex-Date
- Sep 08, 2026
- Dividend Yield
- 0.71%
Clinuvel Pharmaceuticals Limited Sponsored ADR News
CUVL FAQ
What was Clinuvel Pharmaceuticals Limited Sponsored ADR’s price range in the past 12 months?
What is Clinuvel Pharmaceuticals Limited Sponsored ADR’s market cap?
When is Clinuvel Pharmaceuticals Limited Sponsored ADR’s upcoming earnings report date?
How were Clinuvel Pharmaceuticals Limited Sponsored ADR’s earnings last quarter?
Is Clinuvel Pharmaceuticals Limited Sponsored ADR overvalued?
Does Clinuvel Pharmaceuticals Limited Sponsored ADR pay dividends?
What is Clinuvel Pharmaceuticals Limited Sponsored ADR’s EPS estimate?
How many shares outstanding does Clinuvel Pharmaceuticals Limited Sponsored ADR have?
What happened to Clinuvel Pharmaceuticals Limited Sponsored ADR’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Clinuvel Pharmaceuticals Limited Sponsored ADR?
What is the TipRanks Smart Score and how is it calculated?
Clinuvel Pharmaceuticals Limited Sponsored ADR Stock Smart Score
Company Description
Clinuvel Pharmaceuticals Limited Sponsored ADR
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
- Sector
- General
- Industry
- Medical - Pharmaceuticals
- CEO
- Philippe Jacques Wolgen
- Website
- www.clinuvel.com
- Address
- 535 Bourke Street, Melbourne, VIC, 3000, AU
Clinuvel Pharmaceuticals Limited Sponsored ADR (CUVL) Earnings & Revenues
CUVL Company Deck
CUVL Earnings Call
Earnings Call SentimentPositive
The call conveyed a broadly positive operational and financial position: strong recurring profitability, healthy margins, growing cash reserves, strategic reinvestment in R&D and infrastructure, and clear pipeline progress (vitiligo, peptide delivery, NEURACTHEL). Key near-term challenges include U.S. sales moderation due to competitors' trial activity, FX and tax timing effects on reported results, one-off NASDAQ costs, and long timelines for pivotal vitiligo readouts and regulatory interactions. Overall the company presents strong financial resilience and optionality that mitigates current challenges.
View all CUVL earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 5 | 13 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 1 | 0 | 11 |
